Who is sponsoring NCT06311773?

NCT06311773 is sponsored by Aveera Medical, Inc..

What drugs are being tested in NCT06311773?

Interventions in NCT06311773: Boomerang Catheter.

What condition does NCT06311773 study?

NCT06311773 studies Chronic Limb-Threatening Ischemia.

Is NCT06311773 still recruiting?

NCT06311773 is currently enrolling by invitation. Last updated 20 February 2026.

Last reviewed 2026-02-20 · How we verify

NCT06311773

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pivotal Trial of the Boomerang Catheter for pDVA

ENROLLING BY INVITATION NA Last updated 20 February 2026

What this trial tests

NA trial testing Boomerang Catheter in Chronic Limb-Threatening Ischemia in 120 participants. Enrolling by invitation.

Timeline

16 April 2024

Primary endpoint
31 March 2027

31 March 2030

Quick facts

Lead sponsor	Aveera Medical, Inc.
Phase	NA
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	16 April 2024
Primary completion	31 March 2027
Estimated completion	31 March 2030
Sites	19 locations across United States

Drugs / interventions tested

Boomerang Catheter

Conditions studied

Chronic Limb-Threatening Ischemia — all drugs for Chronic Limb-Threatening Ischemia →

Sponsor

Aveera Medical, Inc.

Who can join

18 and older, any sex, with Chronic Limb-Threatening Ischemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to establish the safety and effectiveness of the Boomerang Catheter for percutaneous Deep Venous Arterialization (pDVA) to treat no-option Chronic Limb-Threatening Ischemia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chronic Limb-Threatening Ischemia

Currently open trials in the same condition.

NCT07352800 — Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-thr · Phase 2 · recruiting
NCT06879561 — Pressure Wire Guidance for Infrapopliteal Artery Interventions · NA · recruiting
NCT06071429 — Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease · NA · recruiting
NCT06656364 — Esprit BTK Post-Approval Study · NA · active not recruiting
NCT07330635 — Chronic Wounds and Blood Circulation Detection · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06311773 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aveera Medical, Inc.
Last refreshed: 20 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06311773.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing